Compare REE & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REE | HOTH |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.4M | 18.0M |
| IPO Year | N/A | 2019 |
| Metric | REE | HOTH |
|---|---|---|
| Price | $0.84 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $11.75 | $4.50 |
| AVG Volume (30 Days) | 104.6K | ★ 249.4K |
| Earning Date | 12-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $183,000.00 | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.66 |
| 52 Week High | $11.72 | $3.80 |
| Indicator | REE | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 44.77 |
| Support Level | $0.70 | $1.13 |
| Resistance Level | $0.94 | $1.27 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 48.09 | 66.58 |
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).